Related Experiment Video
Updated: Dec 16, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
[Innovations in systemic treatment of urothelial carcinoma]
Constance Thibault1, Marine Gross-Goupil2
1Service d'oncologie médicale, Hôpital européen Georges-Pompidou, CHU de Paris, 20, rue Leblanc, 75015 Paris, France.
Abstract:
Until 2014, no new therapeutic agent have been approved by authorities in more than 2 decades for bladder cancer. But the panel of treatments has expended in recent years with the emergence of at least 3 different therapeutic classes. First, the immune checkpoint inhibitors that have demonstrated an overall survival benefit in metastatic patients after failure of platinum based chemotherapy. They are therefore currently evaluated alone or in combination with chemotherapy in multiple studies at earlier stages (localized and meta-static). The second and third therapeutic classes are the targeted therapies (especially FGFR inhibitor) and the antibody-drug conjugates with promising results in early clinical trials. In this article, we review all the current and future studies conducted in urothelial carcinoma of the bladder.
Insights
Recent advancements offer new hope for bladder cancer patients. Novel therapies like immune checkpoint inhibitors and targeted drugs are expanding treatment options for urothelial carcinoma.
Area of Science:
- Uro-oncology
- Medical oncology
- Clinical research
Background:
- Bladder cancer treatment options were limited until 2014.
- Recent years have seen significant expansion in therapeutic classes.
- Immune checkpoint inhibitors show survival benefits in metastatic settings.
Purpose of the Study:
- To review current and future therapeutic studies for bladder cancer.
- To highlight the emergence of new treatment modalities.
- To provide an overview of advancements in urothelial carcinoma treatment.
Main Methods:
- Review of clinical trials and therapeutic agent approvals.
- Analysis of immune checkpoint inhibitors' efficacy.
- Evaluation of targeted therapies and antibody-drug conjugates.
Main Results:
- Immune checkpoint inhibitors demonstrate survival benefits in metastatic bladder cancer post-chemotherapy.
- Targeted therapies, including FGFR inhibitors, show promise in early trials.
- Antibody-drug conjugates are emerging as a new therapeutic class with positive early results.
Conclusions:
- The treatment landscape for bladder cancer has rapidly evolved.
- New therapeutic classes offer improved outcomes and options for patients.
- Ongoing research is exploring these agents in earlier stages of urothelial carcinoma.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi VI: Surgical Management
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...

